These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10577989)

  • 21. TNF alpha blockade in rheumatoid arthritis--time for caution or enthusiasm?
    Hamilton JD; Wilson HE; Madhok R; McInnes IB; Capell HA
    Scott Med J; 2001 Jun; 46(3):67-70. PubMed ID: 11501322
    [No Abstract]   [Full Text] [Related]  

  • 22. Active tuberculosis in a patient with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitor.
    Fuchs I; Abu-Shakra M; Gelfer E; Smoliakov A; Ben-Haroch D; Horowitz J; Avnon LS
    Isr Med Assoc J; 2010 Sep; 12(9):579-81. PubMed ID: 21287806
    [No Abstract]   [Full Text] [Related]  

  • 23. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 24. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
    van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
    J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
    [No Abstract]   [Full Text] [Related]  

  • 25. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effectiveness and safety of the treatment with tumour necrosis factor alpha antagonists in rheumatoid arthritis patients].
    Arenere Mendoza M; Navarro Aznárez H; Rabanaque Hernández MJ; Manero Ruiz FJ
    Med Clin (Barc); 2005 Jun; 125(1):35-6. PubMed ID: 15960943
    [No Abstract]   [Full Text] [Related]  

  • 27. Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?
    Lu CY; Williams KM; March L; Bertouch JV; Day RO
    Med J Aust; 2004 Oct; 181(8):457; discussion 457-8. PubMed ID: 15487967
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Verhoeven AC; Boers M
    Ned Tijdschr Geneeskd; 2001 Nov; 145(47):2294-5. PubMed ID: 11760611
    [No Abstract]   [Full Text] [Related]  

  • 29. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
    Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
    Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 31. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do all drugs and treatments for rheumatoid arthritis have the same efficacy?
    Weisman MH
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):298-9. PubMed ID: 18431369
    [No Abstract]   [Full Text] [Related]  

  • 33. Escalated conventional therapy for rheumatoid arthritis patients.
    Smith MD
    Rheumatology (Oxford); 2004 Sep; 43(9):1199; author reply 1199-1200. PubMed ID: 15317963
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of biologic agents in rheumatoid arthritis: introduction.
    Silman AJ
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv3-4. PubMed ID: 21859703
    [No Abstract]   [Full Text] [Related]  

  • 35. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.
    Smolen JS; Breedveld FC; Burmester GR; Combe B; Emery P; Kalden JR; Klareskog L; Maini RN; Numo R; van De Putte LB; van Riel PL; Rodriguez-Valverde V
    Ann Rheum Dis; 2000 Jul; 59(7):504-5. PubMed ID: 10873957
    [No Abstract]   [Full Text] [Related]  

  • 36. Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?
    Caporali R; Codullo V; Cipriani P; Giacomelli R
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii1-vii4. PubMed ID: 30289536
    [No Abstract]   [Full Text] [Related]  

  • 37. The updated guidelines on the use of rituximab in rheumatoid arthritis.
    Lopez-Olivo MA; Tayar JH; Suarez-Almazor ME
    Rheumatology (Oxford); 2011 Dec; 50(12):2153-4. PubMed ID: 21546350
    [No Abstract]   [Full Text] [Related]  

  • 38. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease.
    Kavanaugh AF; Mayer LF; Cush JJ; Hanauer SB
    Am J Med; 2011 Apr; 124(4 Suppl):e1-18. PubMed ID: 21531240
    [No Abstract]   [Full Text] [Related]  

  • 39. New drugs for rheumatoid arthritis.
    Roberts LJ
    N Engl J Med; 2004 Dec; 351(25):2659-61; author reply 2659-61. PubMed ID: 15602032
    [No Abstract]   [Full Text] [Related]  

  • 40. FDA perspective on anti-TNF treatments.
    Schwieterman WD
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I90-1. PubMed ID: 10577981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.